Saved in:
| Main Author: | |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Universidade de Santa Cruz do Sul
2021
|
| Subjects: | |
| Online Access: | https://www.redalyc.org/articulo.oa?id=570471461008 https://www.redalyc.org/journal/5704/570471461008/ https://www.redalyc.org/journal/5704/570471461008/html/ https://www.redalyc.org/journal/5704/570471461008/570471461008.epub https://www.redalyc.org/journal/5704/570471461008/movil https://doi.org/10.17058/reci.v1i1.14581 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Febrile neutropenia management in pediatric onco-hematologic patients: a systematic review Tatiane Berte Siomara Regina Hahn Salud Therapy Pediatrics Febrile Neutropenia Background and Objectives: cancer cases are gradually increasing, and most treatments still cause several adverse reactions, such as myelosuppression. When neutrophils decline, febrile neutropenia (FN) can be triggered, considered an oncological emergency, leaving patients susceptible to infections. Therefore, it is necessary to determine the best treatment, seeking to reduce the risk of complications. The purpose of this review is to identify, in literature, randomized clinical studies that compare different treatments for FN in pediatric onco-hematological patients. Content: a systematic search was carried out on the PubMed database, for randomized clinical studies, from 2009 to 2019, in English, using “Febrile Neutropenia”, “Pediatric”, and “Therapeutics” as descriptors. A total of 233 articles were found, seven of which were selected for review. The most described antimicrobial for FN treatment was Piperacillin/Tazobactam (PIP/TAZ) and its use is justified by its spectrum of action to cover the most frequent microorganisms in patients with FN. The possibility of using oral antimicrobials may be an alternative and should be analyzed. The description of the risk classification criteria is essential to guide the therapy, and new tools, such as the stewardship, add safety to patient care. Conclusion: the most used antimicrobial to treat FN was PIP/TAZ, and the establishment of standardized risk classification scores in pediatric onco-hematological patients is essential to guide clinical management in FN treatment. 2021 artículo científico 2238-3360 https://www.redalyc.org/articulo.oa?id=570471461008 https://www.redalyc.org/journal/5704/570471461008/ https://www.redalyc.org/journal/5704/570471461008/html/ https://www.redalyc.org/journal/5704/570471461008/570471461008.epub https://www.redalyc.org/journal/5704/570471461008/movil https://doi.org/10.17058/reci.v1i1.14581 en http://www.redalyc.org/revista.oa?id=5704 Revista de Epidemiologia e Controle de Infecção application/pdf Universidade de Santa Cruz do Sul Revista de Epidemiologia e Controle de Infecção (Brasil) Num.1 Vol.11